CCEL Cryo-Cell International
- 9.380
- +0.190+2.07%
- 9.490
- +0.110+1.17%
Cryo-Cell International News
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) shares rose 75.3% to $1.49 during Friday's pre-market session. The company's market cap stands at $245.2 million. Cryo-Cell International (AMEX:CCEL) shares i
CRYO-CELL International GAAP EPS of $0.07 Beats by $0.13, Revenue of $7.85M Misses by $0.1M
Cryo-Cell International (CCEL.US): The 2024 Q1 financial report achieved revenue of $7.85 million, previous value of USD 7.82 million, expected value of USD 7.93 million; earnings per share was USD 0.07, previous value was USD 0.09, and expected value was
Cryo-Cell International (CCEL.US): The 2024 Q1 financial report achieved revenue of $7.85 million, previous value of USD 7.82 million, expected value of USD 7.93 million; earnings per share was USD 0.07, previous value was USD 0.09, and expected value was -0.02 USD.
Cryo-Cell International Q1 EPS $0.07 Beats $(0.02) Estimate, Sales $7.85M Miss $7.93M Estimate
Cryo-Cell International (NASDAQ:CCEL) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.02) by 450 percent. This is a 22.22 percent decrease over earnings
Cryo-Cell International 1Q Rev $7.85M >CCEL
Cryo-Cell International 1Q Rev $7.85M >CCEL
Cryo-Cell International 1Q EPS 7c >CCEL
Cryo-Cell International 1Q EPS 7c >CCEL
Press Release: Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results OLDSMAR, Fla.--(BUSINESS WIRE)--April 15, 2024-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the
NYSE American New 52-Week Highs And Lows
New Highs 2 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Cryo-Cell International CCEL 8.11 8,975 FT
Cryo-Cell International Announces Strategic Subsidiary Spin-Off Plans
Cryo-Cell Announces Plans To Explore Strategic Alternatives And Spin-off Celle Corp.
Cryo-Cell Announces Plans To Explore Strategic Alternatives And Spin-off Celle Corp.
NYSE American Net Change Percentage Gainers & Losers
GAINERS COMPANY SYMBOL LAST CHANGE PERCENT VOLUME ------- ------ ---- ------ ------- ------ Neuraxis
Cryo-Cell International: A Buy Rating Anchored in Strong Gross Margins and Long-Term Growth Prospects
CRYO-CELL International GAAP EPS of -$1.14 Misses by $1.26, Revenue of $31.3M Misses by $0.08M
Cryo-Cell International FY23 Rev $31.3M >CCEL
Cryo-Cell International FY23 Rev $31.3M >CCEL
Press Release: Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023 OLDSMAR, Fla.--(BUSINESS WIRE)--February 28, 2024-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"
Strong Performance and Growth Potential Drive Buy Rating for Cryo-Cell International: An Analysis by Allen Klee
Cryo-Cell International Q3 EPS $0.08 Vs. $0.06 Prior Year, Sales $7.87M Beat $7.77M Estimate
Cryo-Cell International (NASDAQ:CCEL) reported quarterly earnings of $0.08 per share. This is a 33.33 percent increase over earnings of $0.06 per share from the same period last year. The company repo
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial Results
Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended
CRYO-CELL International GAAP EPS of $0.03, Revenue of $7.77M
Cryo-Cell International Q2 EPS $0.03 Beats $(0.08) Estimate, Sales $7.77M Inline
Cryo-Cell International (NASDAQ:CCEL) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.08) by 137.5 percent. This is a 57.14 percent decrease over earnin
Analysis
Price Target
No Data
